Skip to content
2000
Volume 11, Issue 5
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

There is an unquestionable need for more effective therapies for pancreatic cancer. Aptamers are single-stranded DNA or RNA oligonucleotide ligands whose 3-dimensional structures are dictated by their sequences. Aptamers have been generated against numerous purified protein targets using an iterative in vitro selection technique known as Systematic Evolution of Ligands by EXponential enrichment (SELEX). Several biochemical properties make them attractive tools for use in an array of biological research applications and as potential pharmacologic agents. Isolated aptamers may directly affect target protein function, or they may also be modified for use as delivery agents for other therapeutic cargo or as imaging agents. More complex selections, using whole cancer cells or tumor tissue, may simultaneously identify novel or unexpected targets and aptamers to inhibit them. This review summarizes recent advances in the field of aptamers and discusses aptamer targets that have relevance to pancreatic cancer.

Loading

Article metrics loading...

/content/journals/acamc/10.2174/187152011795677472
2011-06-01
2025-04-02
Loading full text...

Full text loading...

/content/journals/acamc/10.2174/187152011795677472
Loading

  • Article Type:
    Research Article
Keyword(s): Aptamer; cancer therapy; pancreatic cancer; RNA therapeutic; SELEX
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test